Drug-Eluting Balloon for the Treatment of Failing Hemodialytic Radiocephalic Arteriovenous Fistulas: Our Experience in the Treatment of Juxta-Anastomotic Stenoses
Restricted accessResearch articleFirst published online September, 2014
Drug-Eluting Balloon for the Treatment of Failing Hemodialytic Radiocephalic Arteriovenous Fistulas: Our Experience in the Treatment of Juxta-Anastomotic Stenoses
The purpose of this article is to report our experience with drug-eluting balloons for the treatment of juxta-anastomotic stenoses of failing radiocephalic hemodialytic arteriovenous shunt and to evaluate the primary and secondary patency (PP and SP).
Methods
After approval by the local hospital's Ethical and Scientific Review Board, 26 consecutive patients with juxta-anastomotic stenosis of radiocephalic hemodialytic shunt were treated with angioplasty with drug-eluting balloon. The main objective was to evaluate PP defined, in accordance with the Kidney Disease Outcomes Quality Initiative recommendation, as the absence of dysfunction of the vascular access, patent lesion or residual stenosis <30% and no need for further reintervention of the target lesion (TL). PP and SP at 6, 12 and 24 months were evaluated, with echo color doppler and phlebography, for both arteriovenous fistulae, defined as absolute, and TL.
Results
Immediate postprocedural technical and clinical success was 100% for all the patients; we had only one technical failure in repeated treatments. At 6 months the absolute and TL PP was 96.1%; at 12 months the absolute PP was 81.8%, TL PP 90.9%, absolute SP 95.4%, TL SP 100%; at 24 months the absolute and TL PP was 57.8%; absolute and TL SP 94.7%; only one arteriovenous fistula was lost during the period.
Conclusions
The use of drug-eluting balloons, after standard angioplasty, improves primary patency and decreases reinterventions of TL in juxta-anastomotic stenoses of failing native dialytic arteriovenous shunts.
US Renal Data System.USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010. Chronic kidney disease in the general population. Available at: http://www.usrds.org/2010/pdf/v1_01.pdf. Accessed February 20, 2011.
2.
BittlJ.A.. Catheter interventions for hemodialysis fistulas and grafts.JACC Cardiovasc Interv.2010; 3(1): 1–11.
3.
Beathard GA, Arnold P, Jackson J, Litchfield T; Physician Operators Forum of RMS Lifeline.Aggressive treatment of early fistula failure.Kidney Int.2003; 64(4): 1487–1494.
4.
ClarkT.W., HirschD.A., JindalK.J., VeugelersP.J., LeBlancJ.. Outcome and prognostic factors of restenosis after percutaneous treatment of native hemodialysis fistulas.J Vasc Interv Radiol.2002; 13(1): 51–59.
5.
RajanD.K., BunstonS., MisraS., PintoR., LokC.E.. Dysfunctional autogenous hemodialysis fistulas: outcomes after angioplasty—are there clinical predictors of patency?Radiology.2004; 232(2): 508–515.
6.
AsifA., GadaleanF.N., MerrillD.. Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study.Kidney Int.2005; 67(5): 1986–1992.
7.
Roy-ChaudhuryP.. Endothelial progenitor cells, neointimal hyperplasia, and hemodialysis vascular access dysfunction: novel therapies for a recalcitrant clinical problem.Circulation.2005; 112(1): 3–5.
8.
CollinsA.J., KasiskeB., HerzogC.. United States Renal Data System 2006 Annual Data Report Abstract.Am J Kidney Dis.2007; 49(1 Suppl 1): A6–A7, S1-S296.
9.
Roy-ChaudhuryP., KellyB.S., ZhangJ.. Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies.Blood Purif.2003; 21(1): 99–110.
10.
Roy-ChaudhuryP., SukhatmeV.P., CheungA.K.. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint.J Am Soc Nephrol.2006; 17(4): 1112–1127.
11.
AllonM.. Current management of vascular access.Clin J Am Soc Nephrol.2007; 2(4): 786–800.
12.
NKF-K/DOQI Clinical practice guidelines for vascular access: update 2000.Am J Kidney Dis.2001; 37(1)(Suppl 1): S137–S181.
13.
TonnessenB.H., MoneyS.R.. Embracing the fistula first national vascular access improvement initiative.J Vasc Surg.2005; 42(3): 585–586.
14.
LongB., BrichartN., LermusiauxP.. Management of perianastomotic stenosis of direct wrist autogenous radial-cephalic arteriovenous accesses for dialysis.J Vasc Surg.2011; 53(1): 108–114.
15.
Turmel-RodriguesL.. Dilatation is usually the best treatment for stenosis of the arteriovenous hemodialysis fistula.Nat Clin Pract Nephrol.2008; 4(3): 116–117.
SchwabS.J., HarringtonJ.T., SinghA.. Vascular access for hemodialysis.Kidney Int.1999; 55(5): 2078–2090.
18.
RemuzziA., Ene-IordacheB., MosconiL.. Radial artery wall shear stress evaluation in patients with arteriovenous fistula for hemodialysis access.Biorheology.2003; 40(1-3): 423–430.
19.
PaszkowiakJ.J., DardikA.. Arterial wall shear stress: observations from the bench to the bedside.Vasc Endovasc Surg.2003; 37(1): 47–57.
20.
CorpatauxJ.M., HaeslerE., SilacciP., RisH.B., HayozD.. Low-pressure environment and remodelling of the forearm vein in Brescia-Cimino haemodialysis access.Nephrol Dial Transplant.2002; 17(6): 1057–1062.
21.
Roy-ChaudhuryP., WangY., KrishnamoorthyM.. Cellular phenotypes in human stenotic lesions from haemodialysis vascular access.Nephrol Dial Transplant.2009; 24(9): 2786–2791.
22.
WangY., KrishnamoorthyM., BanerjeeR.. Venous stenosis in a pig arteriovenous fistula model—anatomy, mechanisms and cellular phenotypes.Nephrol Dial Transplant.2008; 23(2): 525–533.
23.
LiL., TerryC.M., BlumenthalD.K.. Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model.Nephrol Dial Transplant.2007; 22(11): 3139–3146.
TerryC.M., KimS.E., LiL.. Longitudinal assessment of hyperplasia using magnetic resonance imaging without contrast in a porcine arteriovenous graft model.Acad Radiol.2009; 16(1): 96–107.
26.
Roy-ChaudhuryP., ArendL., ZhangJ.. Neointimal hyperplasia in early arteriovenous fistula failure.Am J Kidney Dis.2007; 50(5): 782–790.
27.
Roy-ChaudhuryP., SukhatmeV.P., CheungA.K.. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint.J Am Soc Nephrol.2006; 17(4): 1112–1127.
28.
MezzanoD., PaisE.O., ArandaE.. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia.Kidney Int.2001; 60(5): 1844–1850.
29.
LeeT., ChauhanV., KrishnamoorthyM.. Severe venous neointimal hyperplasia prior to dialysis access surgery.Nephrol Dial Transplant.2011; 26(7): 2264–2270.
SreedharaR., HimmelfarbJ., LazarusJ.M., HakimR.M.. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study.Kidney Int.1994; 45(5): 1477–1483.
32.
SchmitzP.G., McCloudL.K., ReikesS.T., LeonardC.L., GellensM.E.. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial.J Am Soc Nephrol.2002; 13(1): 184–190.
33.
GradzkiR., DhingraR.K., PortF.K., RoysE., WeitzelW.F., MessanaJ.M.. Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts.Am J Kidney Dis.2001; 38(6): 1240–1244.
34.
KohlerT.R., ToleikisP.M., GravettD.M., AvelarR.L.. Inhibition of neointimal hyperplasia in a sheep model of dialysis access failure with the bioabsorbable Vascular Wrap paclitaxel-eluting mesh.J Vasc Surg.2007; 45(5): 1029–1037, discussion 1037-1038.
35.
KellyB., MelhemM., ZhangJ.. Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model.Nephrol Dial Transplant.2006; 21(9): 2425–2431.
36.
KatsanosK., KarnabatidisD., KitrouP., SpiliopoulosS., ChristeasN., SiablisD.. Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-month interim results from a prospective randomized controlled trial.J Endovasc Ther.2012; 19(2): 263–272.
37.
SuzukiT., KopiaG., HayashiS.. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model.Circulation.2001; 104(10): 1188–1193.
38.
HeldmanA.W., ChengL., JenkinsG.M.. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis.Circulation.2001; 103(18): 2289–2295.
39.
MoriceM.C., SerruysP.W., SousaJ.E.. RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.N Engl J Med.2002; 346(23): 1773–1780.
40.
StoneG.W., EllisS.G., CoxD.A.. TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.N Engl J Med.2004; 350(3): 221–231.
41.
SousaJ.E., CostaM.A., AbizaidA.. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents.Circulation.2005; 111(18): 2326–2329.
42.
KałuzaG.L., GershlickA.H., ParkS.J.. Comparison of neointimal formation in polymer-free paclitaxel stents versus stainless stents (from the ASPECT and ELUTES randomized clinical trials).Am J Cardiol.2004; 94(2): 199–201.
43.
GershlickA., De ScheerderI., ChevalierB.. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial.Circulation.2004; 109(4): 487–493.
44.
BüllesfeldL., GerckensU., MüllerR., GrubeE.. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I.Z Kardiol.2003; 92(10): 825–832.
45.
StoneG.W., EllisS.G., CoxD.A.. TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.Circulation.2004; 109(16): 1942–1947.
46.
FerraresiR., PalloshiA., ApriglianoG.. Angioplasty of below-the-elbow arteries in critical hand ischaemia.Eur J Vasc Endovasc Surg.2012; 43(1): 73–80.
47.
MicariA., CioppaA., VadalàG.. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry.JACC Cardiovasc Interv.2012; 5(3): 331–338.
48.
ChangC.J., KoP.J., HsuL.A.. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis.Am J Kidney Dis.2004; 43(1): 74–84.
49.
News-Medical.Net. Stent graft outperforms balloon angioplasty. Available at: Accessed April 4, 2005.
50.
HaskalZ.J., TrerotolaS., DolmatchB.. Stent graft versus balloon angioplasty for failing dialysis-access grafts.N Engl J Med.2010; 362(6): 494–503.
51.
RajanD.. Use of stent grafts in dysfunctional hemodialysis accesses.Endovasc Today.2011; 10: 50–57.
52.
KimW.S., PyunW.B., KangB.C.. The primary patency of percutaneous transluminal angioplasty in hemodialysis patients with vascular access failure.Korean Circ J.2011; 41(9): 512–517.
53.
ManthaM., KillenJ.P., BaerR., MoffatJ.. Percutaneous maintenance and salvage of dysfunctional arteriovenous fistulae and grafts by nephrologists in Australia.Nephrology (Carlton).2011; 16(1): 46–52.
54.
MortamaisJ., PapillardM., GirouinN.. Endovascular treatment of juxta-anastomotic venous stenoses of forearm radiocephalic fistulas: long-term results and prognostic factors.J Vasc Interv Radiol.2013; 24(4): 558–564, quiz 565.
